The Italian Medicines Agency has suspended testing of hydroxychloroquine on patients with COVID-19


AIFA, the Italian Medicines Agency has suspended the testing of hydroxychloroquine on patients with COVID-19. The body responsible for the regulatory activity of drugs in Italy informs that it has revoked “the authorization to use hydroxychloroquine for the treatment of SARS-CoV-2 infection, outside clinical trials, both in the hospital setting than home ».

The decision of the suspension by the Italian agency comes after that of the WHO, the World Health Organization, to suspend tests on the efficacy against the hydroxychloroquine coronavirus. WHO motivated its choice by referring to a study from the scientific journal Lancet according to which hydroxychloroquine, in addition to being ineffective for the treatment of coronavirus, could be harmful for those suffering from heart disease.

Today, the French government has also revoked the derogations that allowed the prescription of hydroxychloroquine to COVID-19 patients after the contrary opinion of the High Council of Public Health. The trial of the drug had been authorized in late March, but only for patients considered seriously ill.

– Also read: How to eliminate coronavirus from surfaces

Source link


Please enter your comment!
Please enter your name here